177 related articles for article (PubMed ID: 28408526)
41. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
Krause BJ; Souvatzoglou M; Treiber U
Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
[TBL] [Abstract][Full Text] [Related]
42. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.
Hara T; Kosaka N; Kishi H
J Nucl Med; 2002 Feb; 43(2):187-99. PubMed ID: 11850483
[TBL] [Abstract][Full Text] [Related]
43. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer.
Liu A; Dence CS; Welch MJ; Katzenellenbogen JA
J Nucl Med; 1992 May; 33(5):724-34. PubMed ID: 1569482
[TBL] [Abstract][Full Text] [Related]
44. High-dose salvage radiation therapy for prostate cancer after relapse: in regard to D'Angelillo et al.
Zilli T; Miralbell R
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):681-2. PubMed ID: 25680610
[No Abstract] [Full Text] [Related]
45. The battle on time, money and precision: Da[
Sahnoun S; Conen P; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):2944-2946. PubMed ID: 32715336
[No Abstract] [Full Text] [Related]
46. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
47. Advanced prostate cancer diagnosis and therapy with gallium-67 and yttrium-90, respectively.
Shukla SK; Limouris GS; Cusumano R; Acconcia A; Cipriani C; Atzei G; Argirò G; Boemi S
Anticancer Res; 1997; 17(3B):1731-4. PubMed ID: 9179226
[TBL] [Abstract][Full Text] [Related]
48. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
Fonager RF; Zacho HD; Langkilde NC; Petersen LJ
BMC Cancer; 2016 Jan; 16():10. PubMed ID: 26753880
[TBL] [Abstract][Full Text] [Related]
49. Incidental detection of Leydig cell tumor via fluorine-18-Choline PET/CT in a patient with recurrent prostate cancer disease.
Cimitan M; Hodolič M; Maffione AM; Borsatti E; Urso C; Colletti PM; Rubello D
Clin Nucl Med; 2013 Sep; 38(9):752-4. PubMed ID: 23856823
[TBL] [Abstract][Full Text] [Related]
50. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14).
Fournier P; Dumulon-Perreault V; Ait-Mohand S; Tremblay S; Bénard F; Lecomte R; Guérin B
Bioconjug Chem; 2012 Aug; 23(8):1687-93. PubMed ID: 22770480
[TBL] [Abstract][Full Text] [Related]
51. Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.
Sun Y; Ma X; Zhang Z; Sun Z; Loft M; Ding B; Liu C; Xu L; Yang M; Jiang Y; Liu J; Xiao Y; Cheng Z; Hong X
Bioconjug Chem; 2016 Aug; 27(8):1857-64. PubMed ID: 27399868
[TBL] [Abstract][Full Text] [Related]
52. [Clinical application of fluorocholine positron emission tomography in relapsed prostate cancer].
Oelstrom M; Núñez R; Sanchez P; Sanchez-Saugar E; Garcia-Cañamaque L; Duran I
Actas Urol Esp; 2012; 36(7):444-6. PubMed ID: 22710092
[No Abstract] [Full Text] [Related]
53. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
54. Comparison of bone scintigraphy and
Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
[TBL] [Abstract][Full Text] [Related]
55. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
56. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
57. PET Imaging of FSHR Expression in Tumors with
Pan D; Liu G; Xu Y; Wang Y; Yue Y; Wang L; Yan J; Wang X; Yang R; Yang M
Contrast Media Mol Imaging; 2017; 2017():2674502. PubMed ID: 29097913
[TBL] [Abstract][Full Text] [Related]
58. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
59. The role of PET/CT and current challenges in prostate cancer management.
Lindholm P; Seppänen M; Minn H
Nucl Med Commun; 2009 May; 30(5):325. PubMed ID: 19421025
[No Abstract] [Full Text] [Related]
60. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
